ClinicalTrials.gg
RecruitingNCT07357051Updated Jan 21, 2026

Phase III Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of JKN2301 Dry Suspension in Pediatric Patients Aged 2 to Under 12 Years With Influenza

A Phase 3 interventional study of JKN2301 Dry Suspension and Oseltamivir Placebo in Respiratory Viral Infection, sponsored by Joincare Pharmaceutical Group Industry Co., Ltd. Recruiting at 1 site in China. Open to participants aged 2 Years to 11 Years. Per ClinicalTrials.gov, last updated 2026-01-21.

Sponsored by Joincare Pharmaceutical Group Industry Co., Ltd · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
177
Allocation
Randomized
Ages
2 Years to 11 Years
Sex
All
01

Study summary

The goal of this phase III study is to learn if JKN2301 Dry Suspension works to treat uncomplicated influenza in Pediatric Participants aged 2 to 11 years.

02

Conditions studied

  • Respiratory Viral Infection
03

In context

Lead sponsor

Joincare Pharmaceutical Group Industry Co., Ltd is the lead sponsor of 9 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pediatric patients within the specified age range.
  • Clinical presentation consistent with influenza, confirmed by a positive local rapid test or central laboratory PCR test.
  • Presentation for treatment within the early symptomatic phase of influenza illness.
  • Presence of fever and at least one respiratory symptom.
  • Ability to swallow oral suspension.
  • Parent/guardian and patient (as age-appropriate) able to provide /assent.

Exclusion criteria

Exclusion Criteria:

  • Clinical signs suggestive of severe or complicated influenza infection
  • requiring inpatient management.
  • Presence of a concurrent bacterial infection requiring systemic therapy.
  • Significant , or severe/uncontrolled comorbid conditions.
  • History of to any component of the products.
  • Use of prohibited medications (including other anti-influenza antivirals) within a specified period prior to enrollment.
  • Recent participation in another interventional clinical trial.
  • Any condition that, in the opinion of the investigator, would jeopardize patient safety or compliance with the study protocol.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
177 participants (estimated)

Study arms

  • Experimental
    JKN2301 + Oseltamivir Placebo

    Drug: JKN2301 Dry Suspension · Drug: Oseltamivir Placebo

  • Active comparator
    Oseltamivir + JKN2301 Placebo

    Drug: Oseltamivir · Drug: JKN2301 Placebo

Interventions

  • DrugJKN2301 Dry Suspension

    Single oral dose, administered according to a weight-tiered dosing scheme.

  • DrugOseltamivir Placebo

    Oral suspension, administered twice daily for 5 days, matched to the weight-based dosing of active oseltamivir.

  • Oral suspension, administered twice daily for 5 days according to the approved weight-based dosing regimen.

  • DrugJKN2301 Placebo

    Single oral dose, matched to the weight-tiered dosing scheme of active JKN2301.

06

What researchers measure

Primary outcomes

  1. Incidence, severity, and relationship to treatment of adverse events (AEs) and serious adverse events (SAEs)

    Time frame: Baseline through Day 15

  2. Clinically significant changes in laboratory parameters, vital signs, physical examination, and ECG

    Time frame: Baseline through Day 15

Secondary outcomes

  1. Plasma concentration-time profiles of JKN2301 and its relevant metabolites

    Time frame: At multiple timepoints up to Day 6

  2. Time to alleviation of all influenza symptoms

    Time frame: From treatment initiation up to Day 15

  3. Duration of fever

    Time frame: From treatment initiation up to Day 15

  4. Time to cessation of viral shedding assessed by viral culture

    Time frame: From treatment initiation up to Day 9

  5. Change from baseline in viral titer

    Time frame: Baseline to Day 9

  6. Incidence of influenza-related complications

    Time frame: Up to Day 15

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Jan 2026, 2 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2026
First posted
Jan 21, 2026
StartActual
Nov 7, 2025
Primary completionEst.
Jan 31, 2026
CompletionEst.
Apr 15, 2026
Last update
Jan 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07357051
Responsible party
Sponsor
First posted
Jan 21, 2026
Start date
Nov 7, 2025
Primary completion
Jan 31, 2026 (estimated)
Completion
Apr 15, 2026 (estimated)
Last update
Jan 21, 2026

Study contacts

Ying Yang
Contact
overseas@joincare.com
+86-0755-33268688

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion